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Background: In vitro studies have shown that the active form of vitamin D3, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3),
can regulate differentiation of CD4+ T cells by inhibiting Th1 and Th17 cell differentiation and promoting Th2 and Treg
cell differentiation. However, the serum concentration of 1,25(OH)2D3 is far below the effective concentration of 1,25
(OH)2D3 found in in vitro studies, and it has been suggested that 1,25(OH)2D3 must be produced locally from the
inactive precursor 25-hydroxyvitamin D3 (25(OH)D3) to affect ongoing immune responses in vivo. Although it has been
reported that activated T cells express the 25(OH)D-1α-hydroxylase CYP27B1 that converts 25(OH)D3 to 1,25(OH)2D3, it
is still controversial whether activated T cells have the capacity to produce sufficient amounts of 1,25(OH)2D3 to affect
vitamin D-responsive genes. Furthermore, it is not known how the vitamin D-binding protein (DBP) found in high
concentrations in serum affects T cell responses to 25(OH)D3.
Results: We found that activated T cells express CYP27B1 and have the capacity to produce sufficient 1,25(OH)2D3 to
affect vitamin D-responsive genes when cultured with physiological concentrations of 25(OH)D3 in serum-free medium.
However, if the medium was supplemented with serum or purified DBP, DBP strictly inhibited the production of 1,25
(OH)2D3 and 25(OH)D3-induced T cell responses. In contrast, DBP did not inhibit the effect of exogenous 1,25(OH)2D3.
Actin, arachidonic acid and albumin did not affect the sequestration of 25(OH)D3 by DBP, whereas carbonylation of
DBP did.
Conclusions: Activated T cells express CYP27B1 and can convert 25(OH)D3 to 1,25(OH)2D3 in sufficiently high
concentrations to affect vitamin D-responsive genes when cultured in serum-free medium. However, DBP sequesters
25(OH)D3 and inhibits the production of 1,25(OH)2D3 in T cells. To fully exploit the immune-regulatory potential
of vitamin D, future studies of the mechanisms that enable the immune system to exploit 25(OH)D3 and convert
it to 1,25(OH)2D3 in vivo are required.
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Following antigen recognition CD4+ T cells differentiate
into one of several types of Th cells including Th1, Th2,
Th17 and Treg cells that secrete distinct sets of cytokines
[1-3]. Studies have suggested that, in addition to the cyto-
kine milieu, vitamin D is an important determinant in this
differentiation of CD4+ T cells [4]. Thus, in vitro studies
have shown that the active form of vitamin D3, 1α,25-* Correspondence: cge@sund.ku.dk
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unless otherwise stated.dihydroxyvitamin D3 (1,25(OH)2D3), inhibits production
of IFN-γ and augment the production of IL-4, thereby
limiting Th1 and promoting Th2 cell differentiation [5-9].
Furthermore, 1,25(OH)2D3 inhibits Th17 cell differenti-
ation and induces differentiation of Treg cells [10-12]. It is
therefore generally believed that vitamin D plays an anti-
inflammatory role, and accordingly vitamin D deficiency
has been associated with increased risk of autoimmune
diseases such as type 1 diabetes mellitus [13], lupus ery-
thematosus [14] and multiple sclerosis [15,16].
25-hydroxyvitamin D3 (25(OH)D3) is the inactive pre-
cursor of 1,25(OH)2D3 and is considered the best param-
eter for evaluation of the vitamin D status of a subject.
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1,25(OH)2D3 is approximately 1000-fold lower (60–110
pM) and far below the effective concentration of 1,25
(OH)2D3 found in in vitro studies. Thus, in most in vitro
studies more than a 100-fold higher concentration of 1,25
(OH)2D3 than found in serum is often required to obtain
an effect [7,10-12,18,19]. It has therefore been suggested
that the level of circulating 1,25(OH)2D3 is too low to
affect immune responses in vivo, and that sufficient levels
are obtained by local conversion of 25(OH)D3 to 1,25
(OH)2D3 [20]. In accordance, it has been shown that acti-
vated antigen presenting cells (APC) express the 25(OH)
D-1α-hydroxylase CYP27B1 that converts 25(OH)D3 to
1,25(OH)2D3, and that APC can produce 1,25(OH)2D3
from 25(OH)D3 in vitro and respond to this through the
vitamin D receptor (VDR) in an autocrine fashion [20-23].
Elevated levels of 1,25(OH)2D3 in association with hyper-
calcemia have been observed in patients with sarcoidosis,
tuberculosis, and other infections and inflammatory dis-
eases in which the pathology is characterized by granuloma
formation [24], supporting the hypothesis that activated
macrophages can produce significant amounts of 1,25(OH)
2D3 in vivo.
Like APC, activated T cells express the VDR and
CYP27B1 [20,21,25-29]. However, whether T cells can
convert 25(OH)D3 to 1,25(OH)2D3 in physiological rele-
vant concentrations and respond to this in an autocrine
fashion is a matter of debate. Most studies on the effect of
vitamin D on T cells have not addressed this question as
they investigated the direct effects of supra-physiological
concentrations of 1,25(OH)2D3 and not how 25(OH)D3
affects T cell responses. One study has shown that isolated
T cells have the ability to convert 25(OH)D3 to 1,25(OH)
2D3 in concentrations that actually affects vitamin D-
responsive genes in an autocrine fashion [21]. In agree-
ment, we recently found that purified CD4+ T cells have
the ability to produce substantial amounts of 1,25(OH)2D3
when activated in the presence of 25(OH)D3 [27]. In con-
trast, another recent study found that although activated
T cells do express CYP27B1, the expression level is not
sufficiently high to allow production of 1,25(OH)2D3 in
concentrations that affect vitamin D-responsive genes
[20]. The authors found that 25(OH)D3 only affected T
cell responses when APC were present, and suggested that
APC locally secrete sufficient amounts of 1,25(OH)2D3 to
directly influence the surrounding T cells in a paracrine
fashion.
Other important players influencing the bioavailable
levels of vitamin D are the vitamin D-binding protein
(DBP) and albumin. 25(OH)D3 and 1,25(OH)2D3 circu-
late bound to DBP (85–90%) and albumin (10–15%)
with less than 1% in their free form [30,31]. Studies of
DBP knock-out mice have shown that DBP acts as a
vitamin D reservoir by protecting 25(OH)D3 and 1,25(OH)2D3 from degradation and renal secretion [32].
However, DBP also sequesters 25(OH)D3 and 1,25(OH)
2D3 and inhibits their action on monocytes, DC and ker-
atinocytes in vitro [20,33,34]. How DBP affects T cell re-
sponses to 25(OH)D3 still needs to be determined.
The objectives of this study were to further elucidate
whether T cells have the ability to convert 25(OH)D3 to
1,25(OH)2D3 in proportions that affect a panel of vita-
min D-responsive genes in an autocrine fashion and to
investigate how DBP regulates T cell responses to 25
(OH)D3.
Results
Activated T cells express CYP27B1 and have the capacity
to convert 25(OH)D3 to 1,25(OH)2D3
In order to convert 25(OH)D3 to 1,25(OH)2D3 cells must
express the 25(OH)D-1α-hydroxylase CYP27B1. To deter-
mine whether naïve CD4+ T cells express CYP27B1, we
purified CD45RA+CD4+ cells from the blood of healthy
donors. The resulting cell population contained 95–98%
CD4+ T cells of which more than 96% were CD45RA+
(Additional file 1: Figure S1). The purified cells were stim-
ulated with CD3/CD28 beads for 0–5 days in serum-free
medium and their expression of CYP27B1 mRNA was
subsequently measured. We found that naïve CD4+ T cells
express no or very low levels of CYP27B1. However, the
cells started to express CYP27B1 mRNA shortly after
stimulation, and the expression peaked after 2–3 days of
stimulation (Figure 1A). These results suggested that acti-
vated human CD4+ T cells have the capacity to convert 25
(OH)D3 to 1,25(OH)2D3. To validate this, we stimulated
purified CD4+ T cells in the presence of 100 nM 25(OH)
D3 corresponding to physiological concentrations of 25
(OH)D3 in serum and then measured the production of
1,25(OH)2D3. We found that activated CD4
+ T cells pro-
duced 1,25(OH)2D3 with a kinetic similar to the kinetics
of CYP27B1 expression in the cells, and that the produc-
tion peaked after 3 days of stimulation (Figure 1B). Finally,
to determine whether the cells expressed the receptor for
1,25(OH)2D3, we determined the expression of the VDR
in CD4+ T cells stimulated for 0–5 days. We found that
VDR expression peaked simultaneously with the peak pro-
duction of 1,25(OH)2D3 at day 3 (Figure 1C). Taken to-
gether, these experiments demonstrated that activated
human CD4+ T cells express CYP27B1, that they have the
capacity to convert 25(OH)D3 at physiological concentra-
tions to the active 1,25(OH)2D3, and that they express the
receptor for 1,25(OH)2D3.
Activated T cells have the ability to produce 1,25(OH)2D3
in sufficiently high concentrations to affect vitamin
D-responsive genes
Having demonstrated that activated CD4+ T cells have
the capacity to produce the active form of vitamin D
Figure 1 Activated T cells express CYP27B1 and have the capacity
to convert 25(OH)D3 to 1,25(OH)2D3. (A) Relative CYP27B1 mRNA
expression in T cells activated for 0–5 days normalized to CYP27B1
expression in naïve T cells. Values are given as mean + SEM from 3
independent experiments, *p < 0.05. (B) 1,25(OH)2D3 in the medium of
T cells activated for 0–5 days in the presence of 100 nM 25(OH)D3. Data
are given as mean ± SEM from 3 independent experiments, *p < 0.05.
(C) Representative Western blot of VDR and CD3ζ (loading control)
expression in T cells activated for 0–5 days.
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asked whether the production of 1,25(OH)2D3 was suffi-
ciently high to induce autocrine activation of vitamin D-
responsive genes. To study this, we took advantage of
the finding that the cell surface expression levels of
CD38 on activated T cells are dependent on the concen-
tration of 1,25(OH)2D3 present during T cell activation
[12,35]. Consequently, we activated CD4+ T cells in
serum-free medium in the presence of increasing con-
centrations of 25(OH)D3 or 1,25(OH)2D3 and then mea-
sured CD38 expression at day 3. In accordance with
previous studies, we found that 1,25(OH)2D3 signifi-
cantly up-regulated CD38 expression in activated T cellsin a dose-dependent manner (Figure 2A) [12,35]. In
addition, we found that 25(OH)D3 also induced CD38
up-regulation, suggesting that activated T cells can pro-
duce sufficiently high concentrations of 1,25(OH)2D3 to
affect vitamin D-responsive genes (Figure 2A). We noted
that whereas 25(OH)D3 at a physiological concentration
of 100 nM induced maximum CD38 up-regulation, 1,25
(OH)2D3 was required at a 100-fold higher concentra-
tion (10 nM) than physiological levels (60–110 pM) to
induce the same effect. That a supra-physiological con-
centration of 1,25(OH)2D3 was required to obtain an ef-
fect in our study is in good line with previous studies
[7,10-12,18,19]. However, in contrast to our observations
that 25(OH)D3 at 100 nM had a clear effect on T cells,
most previous studies on 25(OH)D3 required at least a
100-fold higher concentration of 25(OH)D3 than found
in serum to induce an effect [21]. One explanation for
this discrepancy could be that whereas our experiments
were performed in serum-free medium most previous
studies have been performed in medium supplemented
with serum. To study whether the presence of serum
could explain the discrepancy between the concentra-
tions of 25(OH)D3 required to obtain an effect on T
cells, we activated CD4+ T cells in the presence of in-
creasing concentrations of 25(OH)D3 and 1,25(OH)2D3
in medium supplemented with 5% fetal bovine serum
(FBS) and measured CD38 expression at day 3. We found
that the presence of serum significantly shifted the con-
centration of 25(OH)D3 required to induce CD38 expres-
sion (Figure 2B). Thus, compared to serum-free medium
approximately 100-fold higher concentrations of 25(OH)
D3 were required to induce a similar effect on CD38 ex-
pression in T cells cultured in medium supplemented with
serum. In contrast, the presence of serum did not signifi-
cantly shift the concentration of 1,25(OH)2D3 required to
induce CD38 expression. To separately analyse the role of
DBP and albumin in this serum-mediated inhibition of
the effect of 25(OH)D3 on T cells, we activated CD4
+ T
cells in the presence of 100 nM 25(OH)D3 in serum-free
medium supplemented with increasing concentrations of
either DBP or albumin and measured CD38 expression at
day 3. We found that DBP at concentrations above 250–
500 nM completely abolished the effect of 25(OH)D3 on
CD38 expression, whereas albumin did not affect the ef-
fect of 25(OH)D3 (Figure 2C and D).
Although T cells converted 25(OH)D3 to 1,25(OH)
2D3 when activated in serum-free medium, we could
not exclude the possibility that the observed 25(OH)
D3-induced up-regulation of CD38 was caused directly
by 25(OH)D3 and not by 1,25(OH)2D3. To exclude this
possibility, we determined the effect of the CYP27B1
inhibitor ketoconazole on CD38 up-regulation. We ac-
tivated T cells in the absence or presence of ketocona-
zole and increasing concentrations of 25(OH)D3. We
Figure 2 In the absence of serum activated T cells can produce 1,25(OH)2D3 in concentrations that affect CD38 expression. Relative
CD38 cell surface expression on T cells activated for 3 days in X-VIVO 15 (A) or X-VIVO 15 supplemented with 5% FBS (B) in the presence of the
indicated concentrations of 25(OH)D3 and 1,25(OH)2D3 normalized to CD38 cell surface expression on T cells activated in the absence of 25(OH)
D3 and 1,25(OH)2D3. Relative CD38 cell surface expression on T cells activated for 3 days in X-VIVO 15 medium supplemented with increasing
concentrations of DBP (C) or albumin (D) in the presence of 100 nM 25(OH)D3 normalized to CD38 cell surface expression on T cells activated in
the absence of 25(OH)D3. Relative CD38 cell surface expression on T cells activated for 3 days in the absence or presence of ketoconazole and
the indicated concentrations of 25(OH)D3 (E) or 1,25(OH)2D3 (F) normalized to CD38 cell surface expression on T cells activated in the absence of
25(OH)D3 or 1,25(OH)2D3. (A-F) Mean values ± SEM from 3 independent experiments are plotted, *p < 0.05.
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duced CD38 up-regulation (Figure 2E). These observations
indicated that conversion of 25(OH)D3 to 1,25(OH)2D3 is
required for 25(OH)D3-induced CD38 up-regulation. If
this is the case and ketoconazole does not in itself influ-
ence CD38 expression then ketoconazole should not affect
1,25(OH)2D3-induced CD38 up-regulation. Consequently,
we activated T cells in the absence or presence of ketoco-
nazole and increasing concentrations of 1,25(OH)2D3. We
found that ketoconazole did not affect 1,25(OH)2D3-in-
duced CD38 up-regulation (Figure 2F). These experiments
indicated that it is not 25(OH)D3 itself that induces CD38
up-regulation, but that the conversion of 25(OH)D3 to 1,25
(OH)2D3 is required for 25(OH)D3-induced CD38 up-
regulation.
Thus, we could conclude that activated T cells have
the capacity to produce sufficient 1,25(OH)2D3 to affectvitamin D-responsive genes as measured by CD38 expres-
sion when cultured with physiological concentrations of
25(OH)D3 in serum-free medium. However, addition of
DBP to the medium inhibited the effect of 25(OH)D3. In
contrast, DBP did not seem to affect the concentration of
1,25(OH)2D3 required to regulate vitamin D-responsive
genes.
DBP inhibits 25(OH)D3-induced T cell responses
To determine whether the inhibitory effect of DBP on
25(OH)D3 was limited to CD38 gene expression or was
a general phenomenon for vitamin D-responsive genes
in T cells, we studied the influence of 25(OH)D3 and
DBP alone or in combination on the expression of mole-
cules known to be encoded by vitamin D-responsive
genes such as CTLA-4 [7,20], PLC-γ1 [25,36], IL-13 [37]
and IFN-γ [7] in addition to CD38 [35]. We stimulated
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serum-free medium supplemented with either 25(OH)D3
or DBP alone or 25(OH)D3 plus DBP. We confirmed
that 25(OH)D3 up-regulates CD38 mRNA and protein
in activated T cells, and that this up-regulation is com-
pletely inhibited by DBP (Figure 3A and B). Likewise, we
found that the 25(OH)D3-induced up-regulation of
CTLA-4, PLC-γ1 and IL-13 and down-regulation of
IFN-γ was abolished by DBP (Figure 3C-H). Thus, DBP
generally inhibits the effect of 25(OH)D3 on vitamin D-
responsive genes in T cells. To further elucidate the
underlying mechanism behind the inhibition of 25(OH)
D3 in T cells mediated by DBP, we measured the produc-
tion of active 1,25(OH)2D3 in the medium from the cul-
tures described above. We found that in the presence of
25(OH)D3 activated T cells produced significant amounts
of 1,25(OH)2D3; however, addition of DBP completely
abolished the production of 1,25(OH)2D3 (Figure 3I).
Thus, we could conclude that DBP strongly constrains theFigure 3 DBP limits the bioavailability of 25(OH)D3 and inhibits vitam
expression (n = 6) (A) and mRNA expression (n = 4) (B), CTLA-4 expression (n =
mRNA expression (n = 4) (F), IFN-γ production (n = 4) (G) and mRNA expressio
for 3 days in X-VIVO 15 (medium), or X-VIVO 15 supplemented with eithe
(OH)D3 and DBP (25D3/DBP). The mean concentration of IL-13 and IFN-γ
246 pg/ml and 26 ng/ml, respectively. (A-I) Mean + SEM from the numbeeffect of 25(OH)D3 on vitamin D-responsive genes in T
cells by inhibiting the conversion of 25(OH)D3 to 1,25
(OH)2D3.
T cells take up DBP from the environment by
macropinocytosis
DBP is internalized by megalin-mediated endocytosis in
kidney and mammary cells that express megalin and cubi-
lin [38-40]. Megalin-mediated endocytosis of DBP facili-
tates uptake and conversion of 25(OH)D3 to 1,25(OH)2D3
in these types of cells [39,40]. To study whether T cells
can take up DBP from the environment, we incubated
naïve and activated T cells with DBP conjugated to Alexa
Fluor 488 (DBP-AF488). Flow cytometry revealed in-
creased fluorescence of activated T cells compared to
naïve T cells, suggesting that activated T cells take up
DBP-AF488 (Figure 4A). To exclude that the increased
fluorescence simply was caused by DBP-AF488 adhering
to the cell surface of the activated T cells as suggested in ain D-induced gene expression in T cells. Relative CD38 cell surface
4) (C), PLC-γ1 expression (n = 4) (D), IL-13 production (n = 3) (E) and
n (n = 4) (H), and 1,25(OH)2D3 in the medium (n = 6) (I) of T cells activated
r 100 nM 25(OH)D3 (25D3), 1 μM DBP (DBP) or the combination of 25
in the supernatants of cells activated in X-VIVO 15 (medium) was
rs of independent experiments indicated by n in the legend above.
Figure 4 T cells take up DBP from the environment by macropinocytosis. (A) Representative flow cytometry histograms showing DBP-
AF488 fluorescence of naïve T cells and T cells activated for 2 and 4 days and subsequently incubated with 120 nM DBP-AF488 for 12 h at 37°C.
(B) Representative confocal microscopy images illustrating the uptake of DBP-AF488 in activated T cells. DBP-AF488 are shown in green; cell
membrane (TCR) in red; nucleus in blue (DAPI stain). (C) Relative megalin, cubilin, GAPDH and RPLP0 mRNA expression in T cells activated from
0–8 days normalized to the respective mRNA expression in naïve T cells. (D-F) Flow cytometry histograms illustrating DBP-AF488 fluorescence of
activated T cells incubated with 120 nM DBP-AF488 in the absence or presence of (D) RAP (1 μM), (E) unlabelled DBP (12,000 nM), or (F) EIPA
(50 μM). (G) TCR internalization in activated T cells re-stimulated with 30 nM PDBu for 60 min in the absence or presence of EIPA (50 μM). TCR
surface expression of non-stimulated cells was set to 100%. (H-I) CD38 expression (H) and IFN-γ production (I) of T cells activated for 3 days with
the indicated concentrations of DBP in X-VIVO 15 and X-VIVO 15 supplemented with either 25(OH)D3 (100 nM) or 1,25(OH)2D3 (10 nM). (C, G-I)
Data are shown as mean ± SEM from 3 independent experiments.
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croscopy. We found that DBP-AF488 resided in small ves-
icles in the cytosol and could thus conclude that activated
T cells actually take up DBP from the medium (Figure 4B).
To determine whether this uptake might be mediated
by megalin, we measured megalin and cubilin mRNA
expression in naïve and activated T cells. Activated T
cells up-regulated megalin mRNA to a level more than
100-fold higher than in naive T cells, whereas thecubilin mRNA levels were low in both naïve and acti-
vated T cells (Figure 4C). In kidney and mammary cells
megalin-mediated endocytosis of DBP is, in addition to
megalin, dependent on the presence of cubilin at the
cells surface [38,40]. To determine whether DBP was
taken up by megalin-mediated endocytosis in activated
T cells despite their low expression of cubilin, we incu-
bated cells with DBP-AF488 in the absence or presence


































































Figure 5 Neither actin, arachidonic acid or albumin increases
the bioavailability of 25(OH)D3 for T cells. Relative CD38 cell
surface expression on T cells activated for 3 days in the presence of
25(OH)D3 (100 nM) and in the absence or presence of DBP (250 nM)
and the indicated concentrations of (A) actin, (B) arachidonic acid or
(C) albumin. Mean values ± SEM from 3 independent experiments
are plotted.
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that RAP did not influence DBP-AF488 uptake in the T
cells (Figure 4D). Furthermore, blocking antibodies
against megalin and calcium deprivation, known to in-
hibit megalin-mediated endocytosis [39], did not affect
DBP uptake (Additional file 2: Figure S2). In line with
this, high concentrations of DBP did not affect the up-
take of DBP-AF488 (Figure 4E). Taken together these
experiments indicated that DBP is not taken up by
megalin-mediated endocytosis in T cells.
In addition to receptor-mediated endocytosis, cells can
take up extracellular molecules by macropinocytosis.
Macropinocytosis is characterized by its augmentation
by cell activation and that it can be inhibited by amilor-
ide [42,43]. We found that treatment of the cells with
the amiloride analogue 5-(N-Ethyl-N-isopropyl)-amiloride
(EIPA) significantly inhibited uptake of DBP-AF488
(Figure 4F). To ensure that EIPA only blocked macropi-
nocytosis and not receptor-mediated endocytosis, we
measured the effect of EIPA on T cell receptor (TCR) in-
ternalization in parallel. TCR internalization is dependent
on binding of the CD3γ di-leucine based internalization
motif to adaptor molecules of clathrin-coated pits [44,45]
and hence should not be influenced by EIPA. We found
that EIPA did not affect TCR internalization (Figure 4G).
Thus, we could conclude that DBP uptake by CD4+ T cells
is not mediated by megalin-mediated endocytosis but
most likely by macropinocytosis.
Whereas megalin-mediated endocytosis of DBP facili-
tates uptake and conversion of 25(OH)D3 to 1,25(OH)
2D3 in kidney and mammary cells [39,40], macropino-
cytosis of DBP-25(OH)D3 complexes did certainly not
facilitate conversion of 25(OH)D3 to 1,25(OH)2D3 in T
cells (Figure 3). To study whether DBP inhibited the ef-
fects of 1,25(OH)2D3 in the same way as it inhibited the
effects of 25(OH)D3 on T cells, we stimulated CD4
+ T
cells for 3 days in the presence of either 25(OH)D3 or
1,25(OH)2D3 and increasing concentrations of DBP.
After 3 days we measured CD38 expression and IFN-γ
production. We found that in the absence of DBP both
25(OH)D3 and 1,25(OH)2D3 up-regulated CD38 ex-
pression and down-regulated IFN-γ production. How-
ever, whereas addition of DBP clearly inhibited the
effect of 25(OH)D3 it did not influence the effect of
1,25(OH)2D3 on T cell responses (Figure 4H and I).
Neither actin, arachidonic acid nor albumin affect the
DBP-mediated inhibition of 25(OH)D3
In addition to 25(OH)D3 and 1,25(OH)2D3, DBP can
bind actin [46,47] and fatty acids [48,49]. It has been
suggested that binding of fatty acids to DBP decreases
the affinity of DBP for 25(OH)D3 [48,49], and in theory
this could increase the bioavailability of 25(OH)D3 for
immune cells. To study whether binding of actin orarachidonic acid to DBP affected DBP-mediated inhib-
ition of 25(OH)D3-induced T cell responses, we stimu-
lated CD4+ T cells in the absence or presence of DBP
plus 25(OH)D3 and increasing concentrations of actin or
arachidonic acid. We found that neither actin nor ara-
chidonic acid affected 25(OH)D3-induced T cell re-
sponses as measured by CD38 expression (Figure 5A
and B). Since albumin binds 25(OH)D3 with lower affin-
ity than DBP, the ratio between DBP and albumin could
in theory also affect the bioavailability of 25(OH)D3;
however, as for actin and arachidonic acid we found that
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25(OH)D3-induced T cell responses (Figure 5C).DBP carbonylation impedes DBP-mediated inhibition of
25(OH)D3-induced T cell responses
The experiments above demonstrated that activated T
cells have the capacity to convert 25(OH)D3 to 1,25(OH)
2D3 given that 25(OH)D3 is available in a sufficiently
high free concentration but that DBP normally binds
and sequesters 25(OH)D3. The concentration of DBP
relative to 25(OH)D3 determines the ratio of free to se-
questered 25(OH)D3 [50]. The concentration of DBP in
serum is approximately 5 μM, i.e. 50–100 fold higher
than the concentration of 25(OH)D3, and the free to se-
questered ratio of 25(OH)D3 is very low [17,50,51].
However, primary immune responses are most often ini-
tiated in secondary lymphoid organs like lymph nodes
where the concentration of DBP is unknown. It has been
reported that the protein concentration in extracellular
fluid/peripheral lymph might be as low as 5–10% of that
found in serum [52,53], suggesting that the concentra-
tion of DBP in secondary lymphoid organs might be sig-
nificantly lower than the concentration in serum. In
agreement, by semi-quantitative analyses we found that
the concentration of DBP in central lymph from mini-
pigs was approximately 25% of the concentration of DBP
in serum (Figure 6A).Figure 6 DBP carbonylation impedes DBP-mediated inhibition of 25(O
albumin in serial dilutions of plasma and central lymph. (B) Western blot o
subsequently had been derivatized with 2,4-dinitrophenyl hydrazine to det
The membranes were first analysed with anti-DNP antibodies to detect car
re-blotted with anti-DBP antibodies to detect total DBP. (C) Relative CD38
(100 nM) and the indicated concentrations of DBP or carbonylated DBP (Ca
plotted. (D) Representative Western blot analysis of carbonylated DBP and
either derivatized with 2,4-dinitrophenyl hydrazine to detect carbonyl grou
present precipitated DBP diluted 1:4, and lanes 2 and 4 present precipitateAnother mechanism that might decrease the concentra-
tion of functional DBP and thereby increase the availabil-
ity of 25(OH)D3 is carbonylation of DBP. Carbonylation is
a protein modification induced by oxidative stress [54],
and increased carbonylation of serum proteins including
DBP is seen during inflammatory responses [55-57]. Car-
bonylation of DBP could lead to a higher concentration of
free 25(OH)D3 due to a reduced affinity of carbonylated
DBP for 25(OH)D3 and/or increased degradation of DBP.
To investigate this, we activated CD4+ T cells in the pres-
ence of 25(OH)D3 and increasing concentrations of either
unmodified or carbonylated DBP (Figure 6B). We found
that carbonylated DBP did not inhibit the effect of 25(OH)
D3 to the same extent as unmodified DBP as measured by
CD38 expression (Figure 6C). Thus, inflammation-induced
carbonylation of DBP might contribute to an increased
availability of 25(OH)D3 during an immune reaction.
Interestingly, we observed that a fraction of the non-
oxidized purified human DBP was actually carbonylated
(Figure 6B, lane 2). This suggested that carbonylated
DBP is found in human serum as recently described for
rat serum [55]. To investigate whether carbonylated
DBP is found in human serum we immunoprecipitated
DBP from freshly drawn human blood and either deriva-
tized it with 2,4-dinitrophenyl hydrazine to detect carbo-
nylated DBP or left it untreated before Western blot
analysis with anti-DNP antibodies. We found that carbo-
nylated DBP is found in human serum (Figure 6D).H)D3-induced CD38 expression. (A) Western blot of DBP and
f non-oxidized (lanes 1 and 2) and oxidized (lanes 3 and 4) DBP that
ect carbonyl groups (lanes 2 and 4) or left untreated (lanes 1 and 3).
bonylated DBP. Subsequently, the membranes were stripped and
cell surface expression on T cells activated in the presence of 25(OH)D3
rboDBP). Mean values ± SEM from 3 independent experiments are
total DBP (loading control) in human serum. Precipitated DBP was
ps (lanes 1 and 2) or left untreated (lanes 3 and 4). Lanes 1 and 3
d DBP diluted 1:8.
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This study shows that activated human CD4+ T cells ex-
press CYP27B1 and produce sufficient amounts of 1,25
(OH)2D3 to affect vitamin D-responsive genes when cul-
tured in the presence of physiological concentrations of
25(OH)D3 in DBP/serum-free medium.
We found that CYP27B1 expression becomes strongly
up-regulated in activated CD4+ T cells (Figure 1A), and
our results thereby confirm and extend previous reports
on CYP27B1 expression in T cells [20,21,28,29]. How-
ever, although activated T cells express CYP27B1, is has
been discussed whether they actually have the ability to
convert 25(OH)D3 to 1,25(OH)2D3. Thus, some studies
have found that activated T cells can convert 25(OH)D3
to 1,25(OH)2D3 [21,27,28], whereas a recent study found
that T cells do not have this ability [20]. By measuring
1,25(OH)2D3 in the medium of T cells activated in the
presence of 25(OH)D3 we found that CYP27B1 expressed
by the T cells is functional, and that T cells have the
ability to produce significant amounts of 1,25(OH)2D3
(Figure 1B). When determining the capacity of T cells
to convert 25(OH)D3 to 1,25(OH)2D3 the kinetics of
CYP27B1 expression is important to take into account.
We and others [28] found that 1,25(OH)2D3 production
is very low 24 hours after T cell activation but that it
strongly increases 48 hours after activation. We find it
plausible that the missing detection of 1,25(OH)2D3
produced by activated T cells in the study by Jeffery
et al. [20] was due to the fact that the authors measured
1,25(OH)2D3 production after only 24 hours of activa-
tion. Thus, our study clarifies that activated human
CD4+ T cells have the capacity to convert 25(OH)D3 to
1,25(OH)2D3. Furthermore, we demonstrated that acti-
vated T cells have the capacity to produce significantly high
amounts of 1,25(OH)2D3 to affect vitamin D-responsive
genes such as CD38 [35], CTLA-4 [7,20], PLC-γ1 [25,36],
IL-13 [37] and IFN-γ [7] (Figures 2 and 3).
Despite the ability of activated T cells to convert 25(OH)
D3 to 1,25(OH)2D3, addition of DBP to the medium inhib-
ited the effect of 25(OH)D3 on vitamin D-responsive
genes in a dose-dependent manner (Figures 2, 3, 4). Inter-
estingly, DBP did not seem to significantly inhibit 1,25
(OH)2D3-induced T cell responses (Figure 4). The affinity
of DBP for 25(OH)D3 is significantly higher than for 1,25
(OH)2D3 with a Kd of 1.4 nM and 25 nM, respectively
[30,31], and this could be one of the reasons that DBP se-
questered 25(OH)D3 more efficiently than 1,25(OH)2D3.
Megalin-mediated endocytosis of DBP facilitates uptake
and conversion of 25(OH)D3 to 1,25(OH)2D3 in some
types of cells such as renal proximal tubule cells and
mammary epithelial cells [39,40]. We found that activated
T cells express megalin and take up DBP. However, they
do not take up DBP by megalin-mediated endocytosis as
demonstrated by the lack of effect of RAP, blocking anti-megalin antibodies and competition experiments (Figure 4
and Additional file 2: Figure S2). In line with this, previous
studies have demonstrated that megalin-mediated endo-
cytosis of DBP is dependent of the co-expression of cubi-
lin [38], and we found that cubilin expression was very
low in naïve T cells and that it was not up-regulated fol-
lowing T cell activation. Interestingly, we found that EIPA,
which inhibits macropinocytosis, reduced the DBP up-
take. Thus, activated T cells take up DBP, but this up-take
is not mediated by megalin-mediated endocytosis but
most likely by macropinocytosis. In contrast to megalin-
mediated endocytosis that promotes the conversion of 25
(OH)D3 to 1,25(OH)2D3 in kidney and mammary cells
[39,40], macropinocytosis of 25(OH)D3-DBP did not de-
liver 25(OH)D3 for subsequent conversion to 1,25(OH)
2D3 in T cells. Similar results have been found for mono-
cytes that also take up DBP by a megalin-independent
mechanism and where DBP inhibits the conversion of 25
(OH)D3 to 1,25(OH)2D3 [33].
By titrations of 25(OH)D3 and 1,25(OH)2D3 in serum-
free medium, we found that maximal effect on vitamin
D-regulated genes was obtained at 100 and 10 nM, re-
spectively, as assessed by CD38 expression (Figure 2A).
Addition of serum or purified DBP considerably shifted
the concentration of 25(OH)D3 but not of 1,25(OH)2D3
required to affect vitamin D-responsive genes (Figure 2B).
These results support that the physiological concentration
of 1,25(OH)2D3 (60–110 pM) is not sufficiently high to
affect T cell responses, and that a significant local produc-
tion of 1,25(OH)2D3 is essential to reach concentration
(>1000 pM) required to affect T cells as previously sug-
gested [20]. Furthermore, these results indicate that mech-
anisms must exist whereby 25(OH)D3 is released from
DBP and becomes available for the conversion to 1,25
(OH)2D3, given that 25(OH)D3 affects T cell responses
in vivo. In a search for such mechanisms, we investigated
whether actin, arachidonic acid or albumin affected the se-
questration of 25(OH)D3 by DBP, as DBP can bind actin
[46,47] and fatty acids [48,49], and such binding might
affect the affinity of DBP for 25(OH)D3 [48,49]. However,
neither actin, arachidonic acid nor albumin affected the
DBP-mediated inhibition of 25(OH)D3-induced T cell re-
sponses (Figure 5). Local concentrations and/or modifica-
tions of DBP might also affect the availability of 25(OH)
D3 to T cells. Inflammation-induced oxidative stress can
result in oxidative modifications of proteins leading to
protein carbonylation [54-56]. Protein carbonylation is ir-
reversible and leads to disturbances in protein conform-
ation and function [54]. Interestingly, we found evidence
that carbonylation of DBP impedes DBP-mediated inhib-
ition of 25(OH)D3-induced T cell responses (Figure 6).
Thus, inflammation-induced oxidative stress could locally
lead to DBP carbonylation and thereby to a higher con-
centration of free 25(OH)D3. Finally, the DBP gene is
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termed GC1S, GC1F and GC2 have varying affinities for
25(OH)D3, which might also influence the availability and
conversion of 25(OH)D3 to 1,25(OH)2D3 and thereby the
efficiency of 25(OH)D3-induced T cell responses [20,58].
Experiments by nature indicate that significant amounts
of 1,25(OH)2D3 actually can be produced locally by the
involved immune cells during inflammation/infection
in vivo. Thus, elevated systemic levels of 1,25(OH)2D3
can be observed in patients with granulomatous dis-
eases such as sarcoidosis and tuberculosis [24]. The
granulomas are characterized by a central area of activated
macrophages surrounded by activated CD4+ T cells. This
suggests that interactions between activated T cells and
macrophages might induce mechanisms that allow effi-
cient conversion of 25(OH)D3 to 1,25(OH)2D3 in vivo des-
pite the presence of DBP. This is in good accordance with
previous studies which found that treatment of macro-
phages with IFN-γ or soluble CD40L increases their ex-
pression of CYP27B1 and their capacity to convert 25
(OH)D3 to 1,25(OH)2D3 [59-61]. Thus, whether vitamin
D actually affects a given T cell response in vivo probably
relies on a mixture of factors in addition to the concentra-
tion of 25(OH)D3 such as the isotype, local concentration
and degradation rate of DBP and the expression levels of
CYP27B1, the VDR and the 1,25(OH)2D3-24-hydroxylase
CYP24A1 of the cells locally involved in the immune
response.
Conclusions
In summary, activated T cells express CYP27B1 and can
convert 25(OH)D3 to 1,25(OH)2D3 in sufficiently high
concentrations to affect vitamin D-responsive genes when
cultured in serum-free medium. However, DBP sequesters
25(OH)D3 and inhibits the production of 1,25(OH)2D3 in
T cells. To fully exploit the immune-regulatory potential
of vitamin D, further studies of the mechanisms that en-
able the immune system to exploit 25(OH)D3 and convert
it to 1,25(OH)2D3 are required.
Methods
Chemicals
25(OH)D3 (BML-DM100-0001) and 1,25(OH)2D3 (BML-
DM200-0050) were from Enzo Life Sciences, Inc., Ann
Arbor, MI. Stock solutions of 2.5 mM 25(OH)D3 and
2.4 mM 1,25(OH)2D3 were prepared in anhydrous (≥99.5%)
ethanol and stored at −80°C. To determine 1,25(OH)
2D3 in the medium we used the 1,25-Dihydroxy Vita-
min D EIA kit (AC-62F1) from IDS, Tyne and Wear,
UK according to the manufacturer’s instructions. DBP
(A50674H) and albumin (A8763) purified from human
serum were from Meridian Life Sciences and Sigma-
Aldrich, respectively. Actin (A2522), arachidonic acid
(A9673) and ketoconazole (K1003) were from Sigma-Aldrich. Serum and central lymph from mini-pigs were
provided by the Department for Experimental Medicine,
University of Copenhagen, Denmark.Cell culture
Mononuclear cells from blood were isolated by Lympho-
prep (Axis-Shield, Oslo, Norway) density gradient centri-
fugation from healthy donors after obtaining informed,
written consent in accordance with the Declarations of
Helsinki principles for research involving human objects.
The study was approved by the local Ethics Committee
(H-3-2009-132, The Committees of Biomedical Research
Ethics for the Capital Region in Denmark). Naïve CD4+
T cells were isolated, cultured and activated as previously
described [27]. The cells were activated for 3 days in
serum-free X-VIVO 15 medium (1041, Lonza, Verviers,
Belgium) if not otherwise stated.Flow cytometry
For flow cytometry analyses of CD38 and TCR expres-
sion the cells were stained with anti-CD38-APC (HIT2)
or anti-CD3ε-PE (UCHT1) both from BD Biosciences
and analyzed on a FACS Calibur. Fold change in CD38
surface expression was calculated as mean CD38 fluores-
cence intensity of cells stimulated in the presence of 25
(OH)D3/1,25(OH)2D3 divided with mean CD38 fluores-
cence intensity of cells stimulated in the absence of 25
(OH)D3/1,25(OH)2D3. Percent TCR surface expression
was calculated as (mean fluorescence intensity of stimu-
lated cells divided with mean fluorescence intensity of
untreated cells) × 100%.Western blot and ELISA
Western blot analyses were performed as previously
described [27,62]. Following incubation with primary
antibody, the membranes were washed, and the pro-
teins visualized following 60 min incubation at room
temperature with HRP-conjugated rabbit anti-mouse
Ig, swine anti-rabbit Ig or rabbit anti-goat Ig (P0260,
P0399 and P0449 DAKO, Glostrup, Denmark) using
ECL (Amersham Biosciences) technology. The primary
antibodies used were anti-VDR, anti-CD3ζ, anti-CTLA-4
and anti-albumin (D-6, 6B10.2, C-19 and F-8, Santa Cruz
Biotecnology), anti-PLC-γ1 (05–163, Upstate Biotech-
nology), anti-ezrin (3145, Cell Signaling Technology)
and anti-DBP (SAB2501100, Sigma Aldrich). For band
density quantification ECL exposed sheets were analysed
in a ChemiDoc MP Imaging System from Bio-Rad. Meas-
urement of the cytokines IL-13 and IFN-γ were deter-
mined by ELISA according to the manufacturer’s protocol
(Ready-Set-Go; eBioscience).
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mRNA for CYP27B1, CD38, IL-13, IFN-γ, megalin, cubi-
lin, GAPDH and RPLP0 were measured by real-time RT-


















The data were normalized to number of cells by calcu-
lation from the total RNA yield per cell in each sample
(the raw data represents number of target cDNA mole-
cules measured per 12.5 ng total RNA).
DBP uptake and TCR internalization
For studies of cellular uptake of DBP purified DBP
was conjugated with Alexa Fluor 488 (AF488) using a
commercial kit (A10235, Molecular Probes). 120 nM
DBP-AF488 was added to cell cultures of 1 × 106 cells/ml
X-VIVO 15 for 12 h at 37°C. The cells were subsequently
washed and analyzed by flow cytometry. Samples incu-
bated with 120 nM non-conjugated DBP were included as
controls. In some studies the cells were activated for 3
days, washed and resuspended in X-VIVO 15 including
120 nM DBP-AF488 and either 1 μM RAP (Merch Milli-
pore), 20 μg/ml anti-megalin blocking Ab (anti-Megalin
Ab, C-19 and H-245 from Santa Cruz Biotechnology), 4
μM EGTA for calcium deprivation, 12,000 nM non-
conjugated DBP to outcompete possible specific uptake of
DBP-AF488 by receptor-mediated endocytosis or 50 μM
5-(N-ethyl-N-isopropyl)-amiloride (EIPA) (Sigma Aldrich)
an inhibitor of macropinocytosis [43]. For experiments in-
cluding EIPA, DMSO was added to all samples. The cells
were subsequently analysed by flow cytometry. For mi-
croscopy, cells were incubated with DBP-AF488 for 12 h
at 37°C and then stained with anti-CD3 (UCHT1, BD)
followed by an AlexaFluor568 coupled anti-mouse Ig
and DAPI (nuclear staining). The cells were fixed in 1%
paraformaldehyde and analysed by confocal microscopy
(Nikon TE 2000-E). For TCR down-regulation experi-
ments the activated cells were rested for 24 h after re-
moval of the CD3/CD28 beads. Hereafter, the cells wereadjusted to 1 × 106 cells/ml, pre-treated with either DMSO
or 50 μM EIPA dissolved in DMSO for 30 min and then
treated with 30 nM phorbol 12,13-dibutyrate (PDBu)
(Sigma-Aldrich) for 60 min as previously described [63,64].
The TCR surface expression levels were subsequently de-
termined by flow cytometry.
DBP carbonylation and immunoprecipitation
For carbonylation of DBP, 1 mg purified DBP was oxi-
dized in 100 μl oxidation buffer (50 mM Hepes, 100
mM KCl, 10 mM MgCl2, pH 7.4). An additional 100 μl
oxidation buffer including 50 mM ascorbic acid and 200
μM FeCl3 was added and the tube incubated for 15 h at
37°C with shaking. 1 mM EDTA in oxidation buffer was
added to stop the reaction. The solution was transferred
to a VivaSpin500 column (VS0122, Sautorius Stedim
Biotech) and the buffer changed to PBS (column was
spun down once with PBS/1 μM EDTA and twice with
PBS). To test the efficiency of the carbonylation reaction,
Western blot analyses were performed comparing non-
oxidized and oxidized DBP (CarboDBP) after derivatiza-
tion with 2,4-dinitrophenyl hydrazine using the commer-
cial Oxyblot Protein Oxidation Detection kit (S7150,
Millipore) according to the manufacturer’s instruction.
To determine whether carbonylated DBP is found in hu-
man serum, we isolated DBP from freshly isolated hu-
man serum by classical immunoprecipitation [65,66]
using anti-DBP antibodies and protein A coated beads.
The precipitated DBP was either derivatized with 2,4-
dinitrophenyl hydrazine or left untreated before Western
blot analyses with anti-DNP antibodies to detect carbony-
lated DBP. The membranes were subsequently stripped
and re-blotted with anti-DBP antibodies to detect total
DBP.
Statistical analysis
Statistical analyses were performed using Student’s t test
with a 5% significance level, unpaired and paired obser-
vations and equal variance.
Additional files
Additional file 1: Figure S1. Flow cytometric analysis of (A) PBMC and
(B) purified naive CD4+ T cells.
Additional file 2: Figure S2. T cells do not take up DBP by megalin-
mediated endocytosis. Flow cytometry histograms illustrating DBP-AF488
fluorescence of activated T cells incubated with 120 nM DBP or 120 nM
DBF-AF488 in the absence or presence of (A) EGTA (4 μM), (B) anti-megalin
anti-body (20 μg/ml) or (C) EGTA (4 μM) plus anti-megalin antibody (20 μg/ml).
Abbreviations
1,25(OH)2D3: 1α,25-dihydroxyvitamin D3; 25(OH)D3: 25-hydroxyvitamin D3;
VDR: Vitamin D receptor; DBP: Vitamin D-binding protein; APC: Antigen
presenting cell; TCR: T cell receptor; FBS: Fetal bovine serum; RAP: Receptor-
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